OncoPharm

Darolutamide has been FDA-approved. We discuss its differences and similarities to other 2nd-generation anti-androgens (enzalutamide & apalutamide) - especially potential drug interactions!

Our Landmarks in #OncoPharm series returns to the breast cancer patient population to review the landmark 2008 NEJM article from Sparano et al (https://www.nejm.org/doi/full/10.1056/NEJMoa0707056) investigating the optimal taxane regimen to follow adjuvant AC.

A brief discussion on FDA's approval decision on selinexor and its possible role in therapy. Then, a more in-depth details on its MOA, dosing, and toxicity profile.

An overview of pain management principles in cancer patients. Topics covered include the role of NSAIDs, bisphosphonates, and opioids in treating or preventing pain. Also discussed: bowel regimens & opioid conversions.

The Foundations in #Oncopharm series returns with the story of a failed contraceptive candidate that became the first (?) targeted therapy for use in cancer. Tamoxifen's use, MOA, toxicities, and drug interactions are also discussed.

We open up the Ask #OncoPharm inbox to answer a listener question - What advice do you have before starting my PGY2 Oncology Pharmacy Residency?

Discussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)

Dive into the world of cutting-edge cancer treatment with a focus on a newly approved drug for relapsed/refractory diffuse large B-cell lymphoma. Discover the mechanisms behind polatuzumab-vedotin and why it’s considered a game-changer. Hear about its efficacy and safety profiles compared to traditional therapies. Learn the precautions necessary for administration and the promising results that have emerged from clinical trials. This discussion is a must-listen for anyone interested in oncology advancements!

Concise reviews of 6 studies from ASCO '19. #Oncopharm agents discussed include olaparib, ribociclib, pembrolizumab, dabrafenib/trametinib, and *losartan. *caveats apply

Discussing the 1st PI3-kinase inhibitor approved for a solid tumor, alpelisib for HR(+), HER2(-) metastatic breast cancer as 2nd line treatment. Worth sharing with her endocrine/DM colleagues...